Deza G, et al. - Authors gauged the long-term survival and safety profile of etanercept (ETN) in 85 psoriatic arthritis (PsA) patients in tertiary care Spanish hospitals over a 13-year observation period (from 2004 to 2017). This was the largest follow-up period of an ETN-treated population analyzed in a real-life setting. In managing PsA patients, this biologic agent was seen to have a positive safety profile and long-term efficacy. Adverse events (AEs) during therapy were reported in only 12% of the patients, most of them of mild to moderate intensity, and drug discontinuation due to AEs was seen in only 7%.